$ENGN News

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer - Slideshow

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones

EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman

Morgan Stanley Downgrades enGene Therapeutics to Underweight

HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4

EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depart From Co, Effective July 15, 202

enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate

EnGene Therapeutics: The Selloff Creates An Opportunity

A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations

enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain

enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed?

enGene Therapeutics hit by analyst downgrades as drug data disappoints

Why Is enGene Therapeutics Stock Falling Friday?

Citizens Downgrades enGene Therapeutics to Market Perform

Guggenheim Downgrades enGene Therapeutics to Neutral

Wells Fargo Downgrades enGene Therapeutics to Equal-Weight, Lowers Price Target to $2

HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $6

Piper Sandler Downgrades enGene Therapeutics to Neutral, Lowers Price Target to $4